Royalty Pharma (RPRX) Consolidated Net Income (2019 - 2026)

Royalty Pharma has disclosed Consolidated Net Income across 8 years of filings, most recently posting $468.3 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at $468.3 million, up 7.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 23.2% YoY), and the FY2025 annual result was $1.3 billion, changed 0.5% from the prior year.
• Consolidated Net Income came in at $468.3 million for Q1 2026 at Royalty Pharma, up from $355.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $806.4 million in Q3 2024 to a low of -$610.0 million in Q4 2022.
• The 5-year median for Consolidated Net Income is $351.3 million (2023), against an average of $297.3 million.
• Across the five-year window, Consolidated Net Income plunged 1236.61% in 2022 and soared 10266.93% in 2025, its largest moves.
• Royalty Pharma's Consolidated Net Income stood at -$610.0 million in 2022, then jumped by 217.63% to $717.6 million in 2023, then sank by 53.41% to $334.4 million in 2024, then increased by 6.45% to $355.9 million in 2025, then soared by 31.56% to $468.3 million in 2026.
• The last three Consolidated Net Income figures came in at $468.3 million (Q1 2026), $355.9 million (Q4 2025), and $444.2 million (Q3 2025), per Business Quant data.